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The World Health Organization warns that chronic, noncommunicable diseases are rapidly becoming epidemic worldwide.
Escalating rates of neurocognitive, metabolic, autoimmune and cardiovascular diseases cannot be ascribed only to genetics,
lifestyle, and nutrition; early life and ongoing exposures, and bioaccumulated toxicants may also cause chronic disease.
Contributors to ill health are summarized from multiple perspectives—biological eﬀects of classes of toxicants, mechanisms of
toxicity, and a synthesis of toxic contributors to major diseases. Healthcare practitioners have wide-ranging roles in addressing
environmental factors in policy and public health and clinical practice. Public health initiatives include risk recognition and
chemical assessment then exposure reduction, remediation, monitoring, and avoidance. The complex web of disease and
environmental contributors is amenable to some straightforward clinical approaches addressing multiple toxicants. Widely
applicable strategies include nutrition and supplements to counter toxic eﬀects and to support metabolism; as well as exercise
and sweating, and possibly medication to enhance excretion. Addressing environmental health and contributors to chronic disease
has broad implications for society, with large potential beneﬁts from improved health and productivity.
1.Introduction
Common chronic conditions include cardiovascular and ce-
rebrovascular disease, cancer, diabetes, metabolic syndrome,
and obesity, neurocognitive disorders, and immune dysfunc-
tion such as autoimmune disease. These are leading causes
of morbidity and mortality in developed countries, and are
increasingly prevalent in developing nations [1–3].
While average life spans lengthened through recent his-
tory, rising rates of noncommunicable chronic diseases in
younger people mean that escalating numbers are spending
an increasing proportion of their life coping with sickness,
rather than enjoying health [4]. Indeed, chronic diseases as-
sociated with obesity may even turn the tide of improve-
ments in average lifespans [5], previously gained from di-
verse advancements in public health and medicine such as
in maternal and neonatal care and improvements in man-
agement of infectious diseases, trauma, and cardiovascular
events.
Chronicdiseaseiscripplingsomeeconomiesascountries
struggle to develop [3] in the face of rising healthcare costs,
pervasive individual suﬀering, beleaguered families caring
foraﬄictedlovedones,andtruncatedopportunitiesaswork-
ers fall ill during what should be their most productive years.
It was recently conservatively estimated that costs in the
United States of environmental disease in children alone
amounted to a staggering $76.6 billion in 2008, just from
“lead poisoning, prenatal methylmercury exposure, child-
hood cancer, asthma, intellectual disability, autism, and at-
tention deﬁcit hyperactivity disorder” [6]. The wide-spread
implications are vividly illustrated by considering neurocog-
nitive disorders, with a small IQ decrement across society.
As abilities and intellect are reduced among the best and
brightest, we lose potential leaders and innovators, while2 Journal of Environmental and Public Health
simultaneously costs mount for continuing care needed by
largernumbersatthebottomendoftheIQandabilitiesspec-
trum [7].
Searching for reasons for increased chronic diseases in
theyoung,theirailmentscannotbeascribedtoreducedmor-
tality from infectious disease. Similarly, genetics may predis-
pose individuals to chronic disease, but this cannot account
for rapidly increasing prevalence within a generation or two.
This leaves us with pervasive environmental factors [1, 3].
While research centers and international health organiza-
tions devote considerable time and attention to the issue
of toxicant exposure and bioaccumulation of xenobiotics
within the human body [8], direct connections to prevalent
chronic disease are rarely made, and initiatives to tackle
chronic disease may not even mention environmental or
occupational exposures to toxicants, as was the case for a
2010 report prepared for the World Health Organization,
“Tackling Chronic Disease in Europe” [9].
Other prominent authorities such as the U.S. President’s
CancerPaneldecrythatchemicalassessment,regulation,and
enforcementare woefullyinadequate to protect public health
andthatenvironmentalandoccupationalexposuresarerare-
ly suspected or queried in the diﬀerential diagnosis of disease
[10].
In this paper we provide a brief overview of toxicants and
associated mechanisms that may be contributing to chronic
disease, discuss how links between toxic exposures and ad-
verse outcomes are explored and regulated, and outline
measures that may be adopted by health care practitioners
and individuals to improve health. These measures include
reducing exposures, counteracting eﬀects, and enhancing
metabolism and excretion of toxicants.
2. Causesof ChronicDisease
Some chronic diseases may be initiated in susceptible indivi-
duals by single “germs,” such as acquired immune deﬁciency
syndrome (AIDS) from human immune deﬁciency virus
(HIV), ulcers from Helicobacter pylori, or Lyme disease from
Borrelia burgdorferi, but most major chronic diseases do not
have a single cause.
Modiﬁable factors such as smoking, alcohol, lifestyle
(e.g., exercise), and nutrition top lists of contributors to
cardiovascular disease, cancer, and obesity/metabolic syn-
drome/diabetes [1]. The view is weakening that genetic
makeup predestines one to disease, as understanding grows
of potential remediation of biochemical abnormalities un-
derlying genetic predisposition to ill health [11]. Indeed,
a small, shrinking fraction of chronic disease is attributed
directly to genetic makeup, as recently discussed for cancer
[10] and autism [12]. Instead, gene-environment interac-
tions are very plausibly postulated, such as Apolipoprotein-E
4 interactions with heavy metals associated with Alzheimer’s
disease [13] or expression of glutathione genes and mercury
body burden [14]. Such observations led to development of
the ﬁeld of toxicogenomics, with Judith Stern of the Uni-
versity of California at Davis stating, “genetics loads the
gun, but environment pulls the trigger” [15]. In this context,
George Church of Harvard Medical School commented that
the conversation has evolved from, “Here is your destiny, get
used to it!” to “Here is your destiny, and you can do some-
thing about it!” [16].
The related ﬁeld of epigenetics is also coming into fo-
cus. Environmental factors ranging from stress to various
chemicals may alter methylation of DNA, which in turn
modiﬁes DNA expression. Without altering the genetic code,
individuals’ morphology and predisposition to chronic dis-
ease are aﬀected by exposures early in life or even exposures
in previous generations, predating conception [17–19].
2.1. Environmental Contributors to Chronic Disease. In a re-
cent, extensive review of associations between early expo-
sures to various chemicals and chronic disease throughout
life, Cooper et al. highlight the inadequacy of current scien-
tiﬁc methods to tackle the causal puzzle for multiple related
conditions(e.g.,obesity,metabolicsyndrome,cardiovascular
disease, type 2 diabetes, and Alzheimer’s and Parkinson’s
diseases), that may be associated with lower socioeconomic
circumstances (with poorer diet and housing and increased
stress)aswell aswithmultiple potential contributoryenviro-
nmentalfactors(e.g.,airpollution,heavymetals,andvarious
endocrine disrupting chemicals) [20]. The importance of
sowing the seeds of health early in life prompted Leiss and
Kotch to issue a recent “wake-up call” regarding the impor-
tance of environmental health for mothers and children, to
tackle intensive and extensive exposures involved in gene-
environment interactions, impairing development in a mul-
titude of ways [21]. They call for improved environmental
regulation and control, better public education to combat
avoidable exposures that are routinely occurring as a result
of ignorance, more research, environmental justice, and
coverage of environmental health in training of health care
professionals.
With the caveat of noted limitations of reductionist ap-
proaches in examination of environmental causes of chronic
disease, we summarize eﬀe ct so fi d e n t i ﬁ a b l egr o u p so fc h e m -
icals. The point of this summary is neither to depict the
weight of evidence nor to be completely comprehensive but
to illustrate the multiplicity and complexity of relationships
between chemical exposures and health.
2.1.1. Toxic Elements. These elements such as arsenic [22],
cadmium [23], lead [24], and mercury [25] are typically
found in drinking water, foods, dust, ﬁsh, dental amalgams,
consumer products, and old pesticides. They are probable
or established carcinogens that bind with sulphydryl groups
in proteins and inhibit enzyme function, accumulating in
organs such as the brain, kidney, liver, and bone, where
theycauseneurologicaldysfunction,organcompromise,and
skeletal fragility. Among other wide-ranging eﬀects of these
chemicals are endocrine disruption by lead and immune
system impairment by mercury. There are many other
naturally occurring elements of concern, including ﬂuoride,
aluminum, and uranium [26].
2.1.2. Naturally Occurring Substances. These include molds
and their volatile metabolites, as well as animal, plant, andJournal of Environmental and Public Health 3
food allergens. In this context, it is increasingly recognized
that sensitization to a variety of substances does not nec-
essarily involve classic acute reactions, but that sensitivities
to diverse substances, including foods, may be playing a role
in diseases such as autism [27]. In parallel, sensitivities may
arisetodiverseman-madechemicals,notcommonlythought
to be associated with naturally occurring environmental
factors [28–30].
2.1.3. Pesticides. These (e.g., insecticides, herbicides, and
fungicides) have diverse modes of action to kill, repel, or
otherwise control pests (e.g., insects, weeds, and rot fungi).
Pesticidesaretheonlychemicalsmanufacturedandspreadin
the environment speciﬁcally to be toxic, with a tiny fraction
of broadcast/sprayed chemicals reaching their targets. In
her famous book Silent Spring, Rachel Carson detailed eco-
system eﬀects of pesticides following World War II, and
subsequently poisoning of populations and military with
herbicides used in the Vietnam War catapulted pesticides
intothepubliceye.Somepersistentpesticidesnowbannedin
developed countries continue to be used in underdeveloped
countries, and residues are still in the environment and
have accumulated towards the poles. Various present-day
pesticides have been linked to cancers, and neurological,
endocrine, developmental, reproductive, respiratory, and
immunological disorders [31–33]. Pesticides produced in
tissuesofgeneticallymodiﬁedcrops,andalsoappliedinlarge
quantities to exploit crops’ resistance to herbicides, were
recently found in women and cord blood [34]. A popular
meanstoreduceriskistoreservemostpesticidesforthemost
essential uses, but to use least-toxic options for landscaping,
in order to minimize children’s exposure [35].
2.1.4. Persistent Organic Pollutants (POPs). These are a large
group of diverse chemicals deﬁned by their longevity in
the environment and in the body. They include dioxins
and furans (herbicide contaminants, incineration products,
environmental product of antimicrobial “triclosan”), poly-
chlorinated biphenyls and polybrominated diphenyl ethers
(old and newer ﬂame retardants), polyﬂuorinated stain re-
pellents, antiwrinkle and nonstick compounds (e.g., Teﬂon),
and organochlorine chemicals (old pesticides—e.g., hexa-
chlorobenzene, DDT, and metabolite DDE). POPs generally
have low solubilities in water and are lipophilic (or in the
case of some polyﬂuorinated compounds are surfactants,
concentrating at phase interfaces). POPs biomagnify up the
food chain as they accumulate in adipose tissue, where they
may represent a pool of toxicants with diverse health eﬀects
including carcinogenesis [36]. Many POPs with conjugated
ring structures are endocrine disruptors as they interact with
binding sites for hormones. POPs may also bind with the
aryl hydrocarbon receptor (AhR), which elicits a cascade of
“dioxin-like” toxic responses [37]. Knowledge of AhR bind-
ing toxicities led to regulation of chemicals on this basis,
but “nondioxin-like” POPs are also linked to health out-
c o m e ss u c ha sd i a b e t e s[ 38]. Diverse POPs now present a
complex picture in the context of various pervasive health
conditions such as obesity, metabolic syndrome, diabetes,
and endometriosis [39–45].
2.1.5.Volatile OrganicCompounds (VOCs). Theseareanoth-
er large group of chemicals, deﬁned by their lower molecular
weight and volatility [46]. They include solvents, fuels such
as gasoline, and fragrance ingredients [46, 47]. They may
interfere with cellular membranes and cause diverse neuro-
logicaleﬀects.Somesuchasformaldehyde,benzene,andsyn-
theticmusksarecarcinogens,andsomefragranceingredients
are also known sensitizers [29, 30, 48, 49].
2.1.6. Plastics. These are manufactured from monomers,
that are chemically strung together to form polymers. Toxic
concerns regarding various plastic vary widely, with vinyl
standing out for toxicity of the monomer and additives,
as well as challenges with disposal [50]. Unless plastic is
degraded (with heat, ultraviolet radiation or chemical attack,
such as the xenoestrogen bisphenol-A released from poly-
carbonate or epoxy liners in food containers), it is generally
inert, but chemicals dissolved in the plastic may leach out.
“Plasticizers” to improve ﬂexibility or resiliency include en-
docrine disrupting phthalates, and stabilizers and dyes may
contain toxic metals such as lead or cadmium (leading to re-
calls of children’s items such as toys, etc.).
2.2. Mechanisms of Toxicity in Chronic Diseases. The web of
eﬀects and interactions with diverse toxicants aﬀecting mul-
tiple metabolic and physiological pathways may seem to de-
fy reductionist approaches to single-chemical toxicities and
causation of conditions. Nevertheless, with large popula-
tion studies and sophisticated analyses, eﬀects of toxicants
and interactions with toxic as well as beneﬁcial chemicals/
nutrients may be discerned. First, some common biochemi-
cal eﬀects merit highlighting.
2.2.1. Oxidative Stress. This features in development and ex-
acerbation of many chronic conditions [29, 51, 52], such as
allergyandautoimmunity[53,54],cancer[55],cardiovascu-
lar disease [56–58], diabetes [59], neurological compromise
[60], lung disease, and sensitization and pain syndromes [28,
61]. Mitochondria are a particular focus of these eﬀects [62].
2.2.2. Endocrine Disruption. This is apparent in altered pu-
berty and sexual development as well as energy utilization,
glucose sensitivity, and neurological development. Indeed,
interrelated eﬀects on insulin signalling, oxidative stress and
vascular health have prompted Alzheimer’s disease to be
dubbed “diabetes of the brain” [63, 64].
2.2.3. Genotoxicity. This has been studied extensively for
single chemicals but is now recognized as only one aspect
of development of clinically relevant cancers. Immune sur-
veillance, oxidative stress, and stimulation of growth by in-
fections, inﬂammation or endocrine disruption may also
contribute to carcinogenesis or mutagenesis. More common
than changes to DNA sequence are epigenetic changes that
alter expression of the genome, and thereby induce a disease
state [18, 65].
2.2.4. Enzyme Inhibition. This is a direct eﬀect of pesticides
designed to bind with receptors, or of toxic metals that bind4 Journal of Environmental and Public Health
with protein sulfhydryl groups, thereby inactivating a wide
range of enzymes, with diverse adverse eﬀects. For exam-
ple, altered porphyrin proﬁles may be detected with metal
toxicity due to enzyme inhibition [26].
2.2.5. Dysbiosis. Dysbiosis or disruption of the human mic-
robiome has become an area of intense research and clini-
cal interest with the recently initiated Human Microbiome
Project by the US National Institutes of Health (http://com-
monfund.nih.gov/Hmp/). Infection and various toxicants
including some heavy metals have the potential to alter gut
ﬂora, and thus modify various functions of the gastroin-
testinal tract including digestion, bioavailability/absorption,
elimination, detoxiﬁcation, and immune function [27, 66–
69]. Conversely, gut microbes may transform toxicants such
as arsenic or polyaromatic hydrocarbons, altering toxic ef-
fects[70,71].Thesephenomenaelicitdiversehealthsequelae
for the gastrointestinal tract as well as diverse systemic tox-
icitiessuchasinﬂammationandneurologicaleﬀects[72–74].
Other toxicant-related mechanisms of harm are increas-
ingly being recognized, including immune dysregulation
[29],autonomicnervoussystemimpairment[75],biochemi-
cal binding (e.g., carbon monoxide supplanting oxygen on
hemoglobin, or heavy metals supplanting zinc on glutathi-
one), and overall a toxicant induced loss of tolerance (TILT)
[30].
3. Major Chronic Diseases
3.1. Obesity/Metabolic Syndrome/Diabetes. These are linked
in complex ways to diverse POPs, including polychlorinated
biphenyls, dioxins and ﬂame retardants [76]. These chemi-
cals may interfere with thyroid function, and as xenobiotics
stored in adipose tissue are released into the blood stream
during weight loss, they may undermine eﬀorts to lose
further weight [77]. Other toxicants such as arsenic or cad-
mium that increase oxidative stress in the pancreas may also
contribute to diabetes.
3.2. Vascular Disease. This manifests in cardiac, renal, cere-
bral and peripheral disorders. Strong connections with toxic
metalshavebeenestablished,withoxidativestressimplicated
as a central mechanism. Chelation of toxic elements such as
lead may decrease renal impairment [78]. Unfortunately, a
large chelation trial for vascular disease currently under way
is not measuring toxic elements [79].
3.3. Cancer. This is an extensively studied endpoint, with
many carcinogens identiﬁed in occupational settings. Carci-
nogenicity of lower exposures and with mixtures are some-
times less clearly deﬁned, as discussed above. Nevertheless,
there is consensus that there is no “risk-free” or threshold
dose of genotoxic substances. Environmental chemicals may
contribute to cancer by altering DNA or its expression, by
stimulating rapid growth and confounding cell repair mech-
anisms in hormone-sensitive tissues or via inﬂammation, or
by impairing immune surveillance.
3.4. Neurocognitive Impairment. This, including reduced IQ
and aberrant behaviour, is linked to early life exposure to
a wide range of environmental toxicants, including heavy
metals, various POPs and pesticides [80]. Eﬀects may be
immediate (e.g., problems with learning, attention and ag-
gression) or delayed (e.g., increased predisposition to Al-
zheimer’s or Parkinson’s disease). A few common mecha-
nisms include endocrine disruption (e.g., polyhalogenated
biphenyls mimic thyroidhormone),direct inhibition of neu-
ronal growth by toxic metals (e.g., mercury), or interference
with signal transmission by pesticides or toxic metals.
3.5. Multi-System Complaints. Patients signiﬁcantly disabled
with multisystem complaints are increasingly commonly
presenting themselves to clinicians. Recent evidence suggests
that TILT is a pervasive mechanism of illness involving sev-
eral organ systems concurrently [29, 30].
4. Timingand Vulnerabilities
The exquisite vulnerability of the young and unborn was
tragically clear when mothers in Minimata, Japan, who were
coping with relatively mild symptoms from methylmercury
in the ﬁsh they ate, gave birth to children with severe
neurological damage [81]. Unique vulnerabilities of the fetus
and child arise when chemicals interfere with windows of
diﬀerentiation of tissues in utero and during development.
Lead, pesticides, and other chemicals at doses that do not
overtly impair the mother may harm her oﬀspring, with
immediately evident or delayed neurological, endocrine or
other eﬀects [82–85]. Indeed, the mother may impart bioac-
cumulated toxicants (e.g., lead or cadmium from her bones,
or lipophilic pollutants from her adipose tissues) to her fetus
through the placenta, or infant via breast milk. Nevertheless,
breast milk is undoubtedly the best food for infants.
Durationofexposureisanotheraspectoftiming.Haber’s
Rule and related mathematical treatments of toxicity model
that when a toxicant is persistent (or quasipersistent with
ongoingexposuretoaubiquitoustoxicantsuchasbisphenol-
A), or the chemical’s eﬀect is irreversible, then either a low,
chronic dose or a high acute dose may both result in toxic
eﬀects [86]. For many toxicants, there is no “nontoxic” dose.
The public health and regulatory response to this situation is
often to strive for levels that are “as low as reasonably achiev-
able,” typically accompanied by arguments with commercial
enterprisesoverthe“reasonableness”ofcostsofremediation,
abatement, and alternative processes and products.
5. Exposureand Dose
In common usage, “exposure” is sometimes equated with
dosage, with toxicant levels in the environment, drinking
water, foods and products subject to regulation and public
health measures. Nevertheless, toxicologists and health care
professionals parse exposure and doses. For instance, the
presence of a chemical in the environment (e.g., house dust)
does not necessarily mean that a child will crawl in it and
get it on his ﬁngers. Even if he licks his ﬁngers and ingests
the myriad chemicals in house dust, intestinal absorption
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development, nutritional status, and other materials and
foods in the intestine at the same time. The dosage to a tar-
get organ such as the brain will once again be modiﬁed by
absorption into cells and across membranes, and by meta-
bolism and excretion. Measurement of a toxicant in most
target organs or tissues is not feasible in living human study
participants, so surrogate levels may be measured in blood,
urine, hair, sweat, feces, and even meconium, cord blood,
nails and deciduous teeth [82, 87–90].
6. Responses to Toxicants
6.1. Recognition. A potential risk must be recognized before
any response is possible. This includes the classic questions:
what?(isthesubstance),where?(isasubstancemade/found),
how? (does toxicity manifest), who? (may be aﬀected), and
why? (is it used, and are there alternatives that pose less risk).
Beyond prioritization and assessment of chemicals, mea-
sures to reduce environmental and individual exposures oc-
cupy considerable resources of government agencies and
ministries,andinternationalbodiessuchastheWorldHealth
Organization. Increasingly, emissions and product content
data, as well as toxicology data necessary for chemical asses-
sment and registration for use, are being required from in-
dustries, manufacturers and importers.
6.2. Chemical Assessment. Numerous, diverse environmental
exposures merit scrutiny for health eﬀects, including factors
aﬀecting chronic disease. As well as age-old toxic elements
(mercury, lead, cadmium, arsenic, etc.), and allergens and
organic chemicals such as mold metabolites, we and our oﬀ-
spring carry many chemicals in our bodies that mankind has
only recently encountered [8]. Approximately 80,000 novel
chemicalshavebeenregisteredforusewiththeUnitedStates’
Environmental Protection Agency since World War II, but
the vast majority have not been assessed for human health or
environmental eﬀects [91].
Around the world, various approaches are being used
to address the conundrums posed by such vast numbers
of novel chemicals. Environment and health ministries and
regulatoryagenciesinNorthAmericahaveforyearsbeenpri-
oritizing lists of chemicals including pesticides, assessing the
most urgent ones, and restricting uses or banning occasional
chemicals for particular uses. Europe instituted the Registra-
tion, Evaluation, Authorisation and Restriction of Chemicals
(REACH) regulation in 2007, administered by the European
Chemicals Agency (ECHA), placing greater responsibility on
industry to provide data and to manage risk [92].
Risk is typically initially screened on the basis of inherent
toxicity (often acute), whether the chemical is persistent or
bioaccumulative, and the potential for exposure. Toxicolog-
ical risk assessment is carried out by chemical agencies, on
the basis of animal toxicology research supplied by industrial
applicants. Typically a dose level is determined that produces
no (serious) observable adverse eﬀect in an animal, which is
then extrapolated to a lower exposure (e.g., level in air, water,
food, or a product, or an application rate for a pesticide)
that is said to pose a reasonable risk to humans. As long
as the permissible exposure is well above levels observed in
the real world, then the chemical or product may be re-
gistered for sale and use. This paradigm does not address
multiple exposures with potential cumulative or synergistic
eﬀects on a particular system such as the nervous system
[93], although eﬀorts are evolving to assess small groups of
chemicals commonly found together [94], and to carry out
in vitro high throughput, rapid biochemical and cell system
screening, in lieu of animal testing [95].
The catch with toxicological testing is that it would be
illogical for an industry to conduct testing at environmen-
tallyrelevantdoses,becausetheregulatoryframeworkmeans
thatobservationsofeﬀectswillprecluderegistration.Along-
standing tenant of toxicology, that all eﬀects at low doses are
presaged by eﬀects at higher doses, is captured as “The dose
makesthepoison,”acommonparaphraseofParacelsus’writ-
ings from the 16th century. Research now contradicts this
view that toxicity becomes apparent at higher doses and is
not detectable below a certain level, as non-monotonic dose
response curves are well recognized to be usually associated
with endocrine eﬀects [96]. Indeed, the American Chemical
Society, with extensive membership among the chemical
industry, recognizes that low-dose, endocrine disrupting
eﬀectsarescientiﬁcallyundermining thetoxicologicaltesting
that underpins current chemical regulation [97].
Another obvious shortcoming of regulatory animal tox-
icology is that humans are not rodents. Human studies of
toxicants are ethically intransigent, and thus necessarily sub-
ject to limitations of observational studies, but health re-
searchers and professionals argue persuasively why and how
epidemiology could and should be given greater weight in
chemical assessment [98].
Faced with fundamental doubts overshadowing today’s
environmental standards and regulatory decisions, some
countries such as Sweden now consider inherent safety, how
essential a chemical or product is, and whether a less toxic,
lower risk substitute is feasible; this is the Substitution Prin-
ciple, a means to put into operation the Precautionary
Principle [99]. The Substitution Principle is in part a prag-
matic response to the enormity of the numbers and diversity
of anthropogenic chemicals, as well as the logistical impos-
sibility of scientiﬁcally assessing all chemicals, let alone com-
binations [99]. In essence, the least-toxic, and most envi-
ronmentally sustainable options for a particular product or
application are the ones that are permitted. Inclusion of the
null option—that a particular product is not necessary for
society—allows regulators to rule out a number of chemicals
from those needing to be further assessed while providing a
strong incentive for “green” chemistry.
7. Public Health
With rules laid out as to allowable uses and levels of tox-
icants, protection of public health falls into the purview of a
variety of professionals, from environment, agriculture, nat-
ural resource, and health ministries to local public health.
7.1. Monitoring and Detection. Pollution and human expo-
sure may be tracked on many levels, by governments mon-
itoring and reporting toxicants from large scale industrial6 Journal of Environmental and Public Health
Table 1: Selected websites for chemical information.
World Health Organization http://www.who.int/
INCHEM (Chemical Safety Information from
Intergovernmental Organizations) http://www.inchem.org/
Concise International Chemical Assessment Documents
(CICADs) http://www.inchem.org/pages/cicads.html
Environmental Health Criteria (EHC) Monographs http://www.inchem.org/pages/ehc.html
Health and Safety Guides (HSGs) http://www.inchem.org/pages/hsg.html
International Agency for Research on Cancer
(IARC)—Summaries and Evaluations http://www.inchem.org/pages/iarc.html
International Chemical Safety Cards (ICSCs) http://www.inchem.org/pages/icsc.html
IPCS/CEC Evaluation of Antidotes Series http://www.inchem.org/pages/antidote.html
Joint Meeting on Pesticide Residues (JMPR) http://www.inchem.org/pages/jmpr.html
KemI-Riskline http://www.inchem.org/pages/kemi.html
Pesticide Documents (PDs) http://www.inchem.org/pages/pds.html
Poisons Information Monographs (PIMs) http://www.inchem.org/pages/pims.html
Screening Information Data Set (SIDS) for High Production
Volume Chemicals http://www.inchem.org/pages/sids.html
Centers for Disease Control and Prevention (USA) http://www.cdc.gov/
Agency for Toxic Substances and Disease Registry (USA) http://www.atsdr.cdc.gov/
National Institute for Occupational Safety and Health (USA) http://www.cdc.gov/niosh/
Environmental Protection Agency (USA) http://www.epa.gov/
National Institute for Environmental Health and Safety
(USA) http://niehs.nih.gov/
National Toxicology Program (USA) http://ntp.niehs.nih.gov/
European Commission—Public Health http://ec.europa.eu/health/index en.htm/
European Commission—Scientiﬁc Committee on Emerging
and Newly Identiﬁed Health Risks (SCENIHR)
http://ec.europa.eu/health/scientiﬁc committees/emerging/index
en.htm/
European Chemicals Agency http://echa.europa.eu/
emissions; environmental levels in air, water, soil, and wild-
life; individual exposures in foods, drinking water and con-
sumer products; and levels in people themselves with pop-
ulation surveillance. Publicly available data may serve many
purposes, from deciding to avoid vigorous exercise on the
smoggiest days, to investigating contaminated sites and pol-
lution sources in one’s neighbourhood. Governments regu-
larly publish online data such as daily air quality, and may
announce product recalls (e.g., children’s products with lead
or cadmium, or baby formula with melamine). A list of
some helpful websites addressing chemical assessment and
monitoring is provided in Table 1 (many additional sites are
available for individual countries). Nongovernmental orga-
nizations also carry on myriad public education campaigns
such as recommending foods with lower levels of pesticides
[100]orpersonalcareproductswithlowerlevelsofchemicals
of concern [101], or even identifying houses at risk for child
lead exposures [102].
Governmental regulation provides a bottom line for use
of and exposure to potential toxicants, but chemicals have
historicallybeenassumed“innocentuntilprovenguilty,”and
there is a long history of examples such as pesticides being
bannedafterdecadesofuse,andusesandlimitsforchemicals
such as lead falling as scientiﬁc knowledge improves. Evolu-
tion of public health initiatives as risks are recognized may
drive innovation; for instance, more stringent standards are
possible as water and waste treatment technologies improve,
and best practices for pest management change when the
array of permitted chemicals is limited.
Individual choices (e.g., when shopping) will be aﬀected
by education and perception regarding risk, as well as the
cost, feasibility, and identiﬁcation (with honest, meaningful
labelling) of alternatives. Medical practitioners themselves
should be knowledgeable, and have the resources to educate
and facilitate their patients making the best choices for
their personal, family, patient and community health. On a
broader scale, the voice of the medical community has excel-
lent credibility in setting public policy to promote health.
8. ClinicalConsiderationsRegarding Toxicants
The reality of the contemporary world is that toxicants are
ubiquitous and, while avoidance is central to any manage-
ment strategy, toxicants are not entirely avoidable. This has
always been true for naturally occurring elements, but the
recent onslaught of anthropogenic substances poses new
challenges for an individual’s biochemistry and hence for the
clinician.
Although identifying the epidemiologic patterns of tox-
icant exposure and health sequelae has been one focus ofJournal of Environmental and Public Health 7
attention,somewithintheclinicalworldareasking,“Sowhat
dowedoaboutit?”Therealizationthatmanythroughoutthe
world already possess a signiﬁcant body burden of anthro-
pogenic compounds [8, 103], juxtaposed with the emerging
reality of serious potential health sequelae associated with
toxicant accrual has inevitably led some scientists and clin-
icians to consider possible measures to reduce the toxicant
burden in the human body in order to reduce the risks asso-
ciated with accretion of diverse compounds.
Some toxicologists and clinicians, often untrained in en-
vironmental health sciences, consider strategies to eliminate
toxicants from the body to be myths lacking in merit, assum-
ing that all toxicants are metabolized and excreted naturally
and concluding that “there’s nothing that does anything to
hasten the detoxiﬁcation process” [104]. Emerging evidence,
however, challenges this misconception. The contention that
the body has an inherent ability to eliminate quickly all ad-
verse chemical compounds is inaccurate, as many toxicants
with long half-lives accrue in tissues or blood, thus main-
taining long-term potential to inﬂict damage. Metals such
as lead and cadmium, and many halogenated compounds
(e.g.,ﬂameretardants,nonstickcompounds,stainrepellents,
and organochlorine pesticides), are persistent human pol-
lutants with extended half-lives. Unfolding research reveals
ineluctable evidence that various interventions facilitate eli-
mination of retained compounds [87, 105], with the objec-
tive of diminishing the risks associated with biologically
stockpiled poisons. Although more extensive reviews of var-
ious modalities to eliminate toxicants can be found in other
works [105], we present an overview of potential approaches
that can be employed to facilitate the removal of accrued
toxicants.
With a wide range of distinct chemical compounds, each
with a unique chemical structure and a potentially distinct
way of interfacing with human biochemistry, there is no
single mechanism or pathway for the body to eliminate the
whole spectrum of 21st century chemical toxicants. Thus,
when attempting to detoxify the human body, it is ﬁrst im-
portant to explore the speciﬁc accrued toxicants comprising
the total chemical burden, and to employ eﬀective methods
to facilitate excretion of various components.
8.1. Determination of Body Burden of Toxicants. When a pa-
tient with evidence of potential toxicant-related health prob-
lems presents to a clinician trained in environmental health
sciences, an attempt is generally made to identify which ad-
verse chemicals are retained within the body, in order to
employ speciﬁc interventions to address each of these com-
pounds. With the vast array of toxicants that individuals are
exposed to, how does one comprehensively determine which
toxicants are present and then assess the extent of the total
body burden?
As clinical laboratory methods to assess many toxicants
are not extensively validated with meaningful reference
ranges, there is limited ability at this time to investigate a
broad range of speciﬁc chemicals. Blood and urine are most
commonly sampled to assess levels of retained toxicants.
Apart from diﬃculties interpreting results in the absence
of population-speciﬁc reference-limits, these measurements
may be signiﬁcantly ﬂawed as indicators of bioaccumulation
because many compounds sequester in tissues; they do not
remain in blood and may not be readily excreted in urine.
Thus testing of whole blood or serum generally does not
adequately detect toxicants that are being stored primarily
in organs, bone, muscle or adipose tissues [26, 87]. As well,
levels of toxicant compounds in blood and urine can also
ﬂuctuate rapidly as a result of nutrient or pharmaceutical
use,caloricrestriction,hydration,underlyingnutrientstatus,
thermal changes, or exercise [106–110].
For clinical purposes therefore, blood or urine testing to
determine the total body load of toxicants may underesti-
mate the level of accrual for many toxicants. Testing of oth-
er tissues and bodily excretions has also been explored, in-
cluding salivary testing, hair analysis, stool sampling, perspi-
ration testing, breath analysis, provocation testing, as well
as biopsies of fat tissue. Recent evidence conﬁrms, however,
that there are limitations with each of these approaches.
Hair samples, for example may only reﬂect selected toxicant
levels in the blood stream for the last few weeks, while stool
samples only assess what is being eliminated through the
gastrointestinal tract. Fat biopsy research conﬁrms that toxi-
cantssequesterdiﬀerentlywithindiﬀerentfatcompartments,
with toxicant concentrations varying widely among adipose
tissue sites [111]. Although selected testing techniques for
some toxicants can be helpful as an indication of toxicant
bioaccumulation, attempts to accurately and comprehen-
sively delineate the accrued level of each toxicant compound
are impractical clinically and prohibitively expensive. The
results are imprecise at best, and are prone to false negatives
in the sense that a low blood value, for instance, may simply
not reﬂect high levels in the bone, or a vital organ such
as the kidney or brain. Values in urine, hair and feces by
deﬁnition reﬂect the ability to excrete rather than the body
burden of a toxicant, and impaired excretion may result in
greater accretion and potential adverse eﬀects, leading to the
paradoxical ﬁnding that body burden is apparently lower in
a population whose health is in fact being aﬀected by a toxin,
as was seen in children with autism [112–114].
So what is a reasonable clinical approach to patients who
appear to have been harmed by bioaccumulative toxicant ex-
posures?
8.2. Pragmatic Clinical Management. With currently availa-
ble knowledge and technologies, three fundamental clinical
steps should be considered in the initial assessment and pa-
tient care planning for those with potential toxicant-related
health problems:
(a) perform a comprehensive history to endeavour to
identify past and present exposures [115],
(b) order selected toxicant testing as is feasible in each
situation,
(c) use clinical judgement to institute low-risk elimina-
tion strategies directed towards the individual pa-
tient.8 Journal of Environmental and Public Health
Rather than specialized treatments for each speciﬁc tox-
icant identiﬁed, in this paper, we present a general approach
to detoxiﬁcation. This is an ongoing area of research, and
other works are available that provide further particulars
in the management of speciﬁc toxicant categories and indi-
vidual chemical exposures [87, 88, 105].
The clinical approach to human elimination of accrued
compounds generally involves three successive stages:
(1) personal avoidance,




8.2.1. Avoidance. It is sometimes bantered about in environ-
mental health science circles that the three most important
principles in addressing the problem of widespread toxicant
exposure are “avoid, avoid, and avoid.” As previously dis-
cussed, through means of personal education, notiﬁcation
(e.g.,labelling)andactions(e.g.,remediationoflivingspaces
and changes in diet) as well as governmental and indus-
trial regulation with enforcement, minimization of further
exposure is achieved. This is fundamental to any successful
strategy to diminish the toxicant burden of individuals and
populations.
From a clinical perspective, it is useful for the health pro-
vider to perform a detailed inventory of potential exposures.
By means of a meticulous environmental health question-
naire [115], most common exposures can be identiﬁed. An





(iv) olfactory transmission via smell,
(v) vertical transmission (i.e., mother to fetus/infant),
(vi) penetration of body tissues through processes such as
surgery, dentistry, injection, or vector routes.
By identifying exposures and apprising individual pa-
tients regarding where and how they are being contami-
nated, patients are empowered to avoid further chemical
contamination. With ongoing exposures minimized, the hu-
man organism is able to devote resources and energies of
detoxiﬁcation physiology to metabolizing and excreting re-
tained compounds, with less devoted to ongoing exposures.
8.2.2. Securing Eﬃcacy of Endogenous Mechanisms for Toxi-
cant Elimination. The human body has enormous potential
to detoxify foreign compounds through various physiolog-
ical mechanisms. Endogenous detoxiﬁcation of metabolic
w a s t ep r o d u c t sa sw e l la sf o r e i g nt o x i c a n t si sap r i m a r y
physiological function, that requires considerable energy.
Major organs of detoxiﬁcation include the liver, kidney, skin,
and lungs. When toxicants are identiﬁed by physiological
processes within the body, pathways of excretion are mobi-
lized to diminish toxicity and to eliminate the xenobiotic
compounds. The particular pathways used to excrete speciﬁc
substances will depend on the chemical properties of the
particular agent in question. Potential pathways include
metabolism or conjugation to form water-soluble com-
pounds for renal excretion, metabolism to less toxic forms
(e.g., methylation of arsenic), conjugation with biochemicals
such as glutathione for gastrointestinal elimination or intra-
cellular metallothionein binding of heavy metals [26].
The ability to eliminate undesired compounds, however,
depends completely on the physiological functioning and
biochemical status of the individual. Anything that impairs
full functioning of detoxiﬁcation biochemistry, such as
nutritional deﬁciencies, will preclude proper elimination of
toxic substances. Accordingly, it is imperative that health
providers understand the fundamentals of detoxiﬁcation
physiology and biochemistry to secure functioning of the
organs of elimination [26].
Clinical history and physical examination can provide
clues to the status of physiological function and potential
causes for impairment. A history of substance use, for exam-
ple alcohol or medications known to be hepatotoxic, can be
helpful in assessing liver function. Nutritional biochemistry
testing, urinary organic acid testing, and biochemical mark-
ers for function of organs such as liver and kidney, can be
employed to assess physiological status and function. Any
impediment to proper physiological functioning should be
addressed.
Remediation of disordered nutritional biochemistry is a
fundamental component of patient care. For example, the
protein molecule glutathione is a prerequisite component of
cellular detoxiﬁcation as well as an essential pillar in hepatic
conjugation biochemistry. Individuals with ongoing expo-
sures or toxicant bioaccumulation often have diminished
stores of glutathione, and thus require ongoing repletion.
Optimal nutrition through dietary instruction, correction of
disordered biochemistry and physiology, and use of directed
supplementation as dictated by laboratory testing is required
for eﬃcient physiological functioning of elimination path-
ways.
It has also been observed that despite biochemical com-
petency, the human organism is not able to excrete some
chemical toxicants eﬀectively. A major reason for the failure
of some compounds to be eradicated eﬀectively is because
of recycling within the body through reabsorption in the
enterohepaticcirculation[116]orreuptakeinkidneytubules
[117]. Accordingly, some toxicants are conjugated and
released from tissues into the bloodstream for excretion,
but are then reabsorbed back into the body. Additionally,
some retained compounds deposit in speciﬁc tissues such as
bone, fat, and muscle, where they will bioaccumulate and
alter physiological functioning within these tissues. Some
compounds will also remain in blood to some degree, freq-
uently bound to plasma proteins [88]. Interventions to en-
hance excretion of retained compounds can be invaluable in
diminishing morbidity associated with toxicant accrual.
Environmental determinants such as toxicant bioaccu-
mulation in some situations may interfere with normalJournal of Environmental and Public Health 9
physiological function and thus necessitate intervention. For
example, vitamin D (an essential biochemical that regulates
geneticexpression,andfacilitatesabsorptionofcalciumfrom
the gut) may potentiate absorption of toxic elements such
as lead, aluminum, and cadmium, that in turn may impair
metabolismofvitaminD[118].Mercurycontaminationmay
alter gastrointestinal absorption of required nutrients result-
ing in deﬁciencies and thus precluding normal physiology.
Some persistent organic pollutants released from adipose
tissue during weight loss, caloric restriction or exercise
may suppress thyroid function [77]. Adverse eﬀects from
toxicant bioaccumulation may cascade within the body—
some toxicants, for example, may alter immune function,
which may in turn spawn autoimmunity [119]a n dt h u s
engender abnormal physiological functioning. In diﬃcult
cases, consultation with experienced environmental health
specialists may be required.
8.2.3. Directed Interventions to Facilitate Removal of Accrued
Toxicants. Empirical research has shown that various strate-
gies can be employed to assist with the eﬀective removal
of some accrued toxicants. Research into such strategies,
however, remains at an early stage in the continuum of clin-
ical science as the problem of widespread toxicant bioac-
cumulation is a newly recognized phenomenon for clinical
medicine. Accordingly, adequate evidence-based research to
objectively conﬁrm or refute the alleged eﬃcacy of assorted
“detox strategies” is often lacking. A few strategies and a gen-
eral approach to clinical detoxiﬁcation are highlighted here
for consideration. A more detailed discussion of commonly
employed strategies to facilitate detoxiﬁcation can be found
elsewhere [105].
8.2.4. Thermal Depuration (Sweating). The skin is a major
organ of detoxiﬁcation, and a vast array of toxicants are able
to be excreted to diﬀering degrees via perspiration [87, 105,
120]. Various researchers and clinicians have endeavoured
to take advantage of this dermal mechanism to facilitate
excretion of accrued compounds and toxicological biomon-
itoring has conﬁrmed that body burdens of many toxicants
diminish with therapy to induce sweating [105, 121, 122].
Some chemical agents such as perﬂuorinated compounds,
however, do not seem to be readily excreted [88]. Despite
much attention given to saunas with heaters emitting at
speciﬁc electromagnetic frequencies, research to date sug-
gests that there is no diﬀerence in toxicant excretion rates
betweenperspirationthatoccursthroughinfraredsauna,dry
or wet regular saunas, or exercise [87, 123].
8.2.5. Selected Medications. T h e s ep e r f o r mau s e f u lr o l ei n
facilitating the elimination of some compounds. For exam-
ple, judicious use of chelators, or agents which strongly bind
to some toxic elements have been demonstrated to assist in
the removal of such toxicants [124, 125]. Chelating agents
such as dimercaptosuccinic acid (DMSA) are generally safe
and eﬀectively bind to metals such as lead and mercury
to enhance excretion rates and to prevent enterohepatic
reabsorption of these compounds [125]. Marked clinical
improvement has been noted in metal contaminated pa-
tients who have been treated with use of such medications
[126]. The use of concomitant strategies, such as foods
and supplements to increase glutathione, to enhance mobil-
ization of toxicants from tissue storage sites may signiﬁcantly
increase the rate of elimination from the body when used
along with chelators.
Bile acid sequestrants such as cholestyramine have re-
cently garnered increasing attention as compounds that bind
to some persistent compounds in the gastrointestinal tract
to prevent enterohepatic reabsorption [88]. These agents
may be useful with such persistent agents as perﬂuorinated
compounds [88] and have been clinically eﬀective in patients
with mycotoxin accrual after mold exposure [127]. As medi-
cal interventions to enhance elimination of toxicants is a
newer area of clinical research, much remains to be studied
in order to develop evidence-based medication protocols for
the removal of some toxic compounds.
8.2.6. Selected Foods and Supplements. Direct evidence of
speciﬁc beneﬁts in humans of diet and dietary supple-
ments is often of limited applicability beyond the subject
population, because of interactions with factors such as
regional environment (e.g., cadmium or selenium in the
soil), lifestyle, dietary practices, levels of nutrients such as
v i t a m i nDf r o ms u ne x p o s u r e ,p o v e r t y ,a n da l c o h o la n d
tobacco use. Some medical evidence exists, however, that
nutritional status (e.g., calcium, zinc and iron repletion)
modiﬁes absorption of toxic elements such as lead, and that
beneﬁcial eﬀects of omega-3 fatty acids and selenium in
ﬁsh somewhat counteract toxicities of methylmercury and
persistent organic pollutants [128, 129].
Research questions are often much more amenable to
animal and tissue culture research, and this body of evidence
has conﬁrmed traditions that some foods and supplemental
nutrients are enormously valuable in facilitating excretion
and reducing biochemical toxicities of toxicants. Although
by no means an exhaustive list, some supplements include
curcumin in the spice turmeric [130], alliums [131], plant
ﬂavonoids such as quercetin [132], selenium [133], algal
products Parachlorella [134, 135]a n dChlorella [136, 137],
naturally occurring organic acids [138], folate requisite min-
erals, and dietary ﬁbre [139] as well as mixed antioxidants
[140]a p p e a rt ob eo fg r e a tv a l u et or e d u c et h ed a m a g e
associatedwithtoxicantexposure.Themechanismsofaction
may include preventing absorption of toxicants, facilitating
elimination of accrued toxic compounds, hindering enter-
ohepatic recycling of some persistent compounds, and di-
minishingtoxicitythroughprotectivemechanisms.Insoluble
carbohydrate and other ﬁbre consumed in the diet, for ex-
ample, appears to act like a sponge and increases the removal
of adverse agents such as mycotoxins and POPs, perhaps
by diminishing reabsorption through the enterohepatic cir-
culation, and thus increasing elimination.
One example is a supplemental product called Chlorella,
an algae from the sea, that has recently garnered much
research attention for its unique properties in facilitating
detoxiﬁcation and preventing absorption of adverse com-
pounds [134–137]. Recent research papers reported animal
results where Chlorella appears to induce the excretion of10 Journal of Environmental and Public Health
mercury [135] and lead [134]. Ongoing study continues
to elucidate the range of compounds that are bound and
removed with Chlorella as well as with other assorted foods
and supplemental nutrients. A caution, however, is that sup-
plements may potentially contain toxicants that accrued as
they grew, such as Chlorella and other biosorbents that are
also noted for their ability to sequester toxic elements from
their environment [141], ﬁsh oil that may contain POPs
[142], or other products that may be contaminated for other
reasons [143].
8.2.7. Other Detoxiﬁcation Modalities. With increasing re-
cognition of ubiquitous toxicant exposure and bioaccum-
ulation [8], a plethora of treatments called “cleanses” have
become commonplace. Furthermore, “detox” clinics have
sprung up throughout the western world allegedly to help
individuals rid their bodies of accumulated toxicants. Unfor-
tunately, there is limited research on many of the programs
andtherapiesthatarecommonlyusedandscientiﬁcevidence
is often lacking to support the audacious claims frequently
made to vulnerable, sick people. While some interventions
such as exercise [144, 145], induced sweating [87, 120],
selected medications [124, 146] (including in those children
with autism who have elevated levels of heavy metals [113,
147]), plasmapheresis [148, 149], some foods and some
supplements [137, 138, 150], and other modalities show
credible evidence of eﬃcacy in removing toxicants, much
research remains to be done in order to yield consistent
evidential support for the increasing plethora of “detox”
interventions. Using data available to date, a basic approach
that can be used clinically, that incorporates the three suc-





(1) A detailed environmental history and exposure in-
ventory, followed by patient education to eﬀect adeq-
uate avoidance [115].
(2) Speciﬁc toxicological testing if indicated according to
the patient history [151].
(3) Remediation of abnormal biochemistry, as identiﬁed
by laboratory investigations [26].
(4) A combination of optimal diet and supplemental nu-
trients may be utilized to secure adequate nutrition
and suﬃcient biochemical reserve for detoxiﬁcation
[152]. Some examples include (this is not a compre-
hensive list) the following:
(a) glutathione [153] and sulfur-containing foods
(e.g., eggs, brassicas and alliums) and sup-
plements such as N-acetylcysteine, taurine or
methylsulfonylmethane to support glutathione
and metallothionein synthesis,
(b) folateandrelatednutrients(e.g.,forarsenicme-
tabolism and excretion [154]),
(c) lipoic acid therapy may assist in detoxiﬁcation
of some compounds including mycotoxins re-
sulting from exposure to certain molds [150],
(d) adequate minerals such as calcium, iron and
zinc, to reduce absorption of heavy metals
[128],
(e) Chlorella to decrease absorption and enhance
excretion of toxicants is generally well tolerated
[134–136, 155],
(f) ﬁber to reduce absorption and facilitate elimi-
nation [139].
(5) Regular sweating (with mineral repletion), with exer-
cise or in a sauna, can facilitate transdermal excretion
[87].
(6) Daily exercise will enhance eliminate of some toxi-
cants [144, 145].
(7) Directed therapies for retained toxicants (as deter-
mined by laboratory investigations) may be imple-
mented [88, 105].
9.1. In Summary. Health care professionals in government
ministries, public health, research, and the clinic will only
be successful against the onslaught of chronic, debilitating
diseases once environmental contributors are recognized,
researched and addressed. Clinical intervention to preclude
further exposure and to detoxify the body of toxicants can
be life changing for aﬄicted individuals [126]. In an epoch
marred by the unleashing of numerous untested chemi-
cal toxicants, basic knowledge of environmental medicine
should be provided in the training of all health care work-
ers. History repeatedly demonstrates, however, that the
translation of emerging scientiﬁc information with adoption
of required clinical skills is usually not expeditious [156,
157]. Hopefully, in our modern era of rapid information
transfer, the process of widespread problem recognition and
solutionimplementationwillbeexpeditedtostemthetideof
chronic disease that is said to be poised to bankrupt health-
care systems.
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